JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ --
TapImmune Inc., (OTCMKTS: TPIV) a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that it has relocated its corporate headquarters from Seattle, Washington, to Jacksonville, Florida, located at 50 North Laura Street, Suite 2500, Jacksonville, Florida 32202.
In making the announcement, Dr. Glynn Wilson, Chairman & CEO of TapImmune said, "Our move to Jacksonville from Seattle allows us to be in closer proximity to our expanded collaboration with investigators at the Mayo Clinic in Jacksonville. Currently, several members of our management team are already residents in Florida, and we are now in closer proximity to the capital markets in New York as well. We believe this move is not only an important event for the Company but also for the Jacksonville area and for the Florida biotech community."
TapImmune is conducting clinical trials and R&D programs to explore the promising commercial potential of its comprehensive approach to immune-oncology in multiple types of cancer and metastatic disease. The Company has exclusive licenses or License Option agreements with Mayo Clinic to commercialize HER2/neu and Folate Receptor Alpha technologies which have completed two successful Phase 1 trials in breast and ovarian cancer at the Mayo Clinic. In both trials the vaccines were safe and generated a robust T-cell response in 90+% of patients treated. Within the next three to twelve months TapImmune expects to commence several Phase 2 studies in triple negative breast, HER2/neu positive breast and ovarian cancer. A large Phase II study in triple negative breast cancer will be fully funded by a $13.3 Million U.S. Department of Defense grant awarded to the Mayo Clinic and will start in 2016.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease. The Company's peptide or nucleic acid-based technologies comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. These technologies provide off-the-shelf therapies that can be used as stand-alone treatments or in conjunction with other approved products, to transform the way cancer is treated.
More information on TapImmune can be found on the company's website: http://www.tapimmune.com, and in a recent TV interview with ABC-TV Network News: http://www.abcactionnews.com/news/mayo-clinic-gets-13-million-grant-from-department-of-defense-for-medical-trials
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
For more information contact:
SOURCE TapImmune Inc.